Karp Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Karp Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-650	Closed	-$74K	–	113
2015 Q3	$74K	Sell	650 -18,160	-97%	-$2.4M	0.05%	149
2015 Q2	$2.54M	Buy	18,810 +2,765	+17%	+$367K	1.71%	19
2015 Q1	$2.08M	Buy	16,045 +2,095	+15%	+$263K	1.41%	27
2014 Q4	$1.61M	Buy	+13,950	New	+$1.57M	1.17%	30

Other funds holding BBH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

VFAM

Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Karp Capital Management's BBH Position: Q4 2015 in Review

Karp Capital Management sold out of VanEck Biotech ETF (BBH) in Q4 2015, closing a stake of 650 shares — an estimated $74K sold.

Karp Capital Management first reported a position in BBH in Q4 2014 and held it in 4 quarters. The position peaked at $2.54M in Q2 2015. 90 funds tracked by Wall St. Rank hold BBH as of Q4 2015.

Karp Capital Management reported no remaining VanEck Biotech ETF position as of Q4 2015 after selling out during the quarter.
Karp Capital Management sold 650 VanEck Biotech ETF shares in Q4 2015, an estimated $74K.
Karp Capital Management first reported a position in VanEck Biotech ETF in Q4 2014 and held it in 4 quarters.
Karp Capital Management's VanEck Biotech ETF position peaked at $2.54M in Q2 2015.
90 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2015.

Based on Karp Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.